Javascript must be enabled to continue!
Kinetics of the Antibody Response to Type III Pneumococcal Polysaccharide
View through CrossRef
Abstract
When the number of PFC present in the spleen was measured at 24-hr intervals after immunizing with an optimally immunogenic dose of type III penumococcal polysaccharide (SSS-III), maximal numbers of PFC were attained 4 days after immunization; thereafter, the number of PFC decreased rapidly. By contrast, serum antibody levels, which were measured in the same mice using a Farr test, reached peak values 5 days after immunization and then declined much more sowly than did the number of PFC. Two factors were found to contribute to this disparity. First, experiments conduceted with splenectomized mice showed that extrasplenic antibody synthesis, which began between days 3 and 4 after immunization and peaked on days 6 to 7, accounted for nearly one-third of the total amount of serum antibody produced. Second, the average rate of antibody synthesis by PFC increased through day 6 after immunization and then declined.
Antigen-antibody dissociation tests showed that the avidity of the serum antibody obtained 4 to 7 days after immunization was the same. Moreover, during the same interval, all the antibody detected by the Farr test was of the IgM class. Thus, a change in avidity or class of immunoglobulin after day 5 did not account for the disparity observed. The clearance rate of antibody injected i.v. into nonimmune and immunized mice was studied. The data obtained indicated that accelerated clearance of antibody was occurring prior to day 3 after immunization; however, after day 3 the antibody clearance rate was constant and was the same as that found when antibody was injected into nonimmune mice. These findings affirmed the results of previous studies showing that treadmill neutralization was not important in determining the serum antibody levels present after immunization with an optimally immunogenic dose of SSS-III.
Oxford University Press (OUP)
Title: Kinetics of the Antibody Response to Type III Pneumococcal Polysaccharide
Description:
Abstract
When the number of PFC present in the spleen was measured at 24-hr intervals after immunizing with an optimally immunogenic dose of type III penumococcal polysaccharide (SSS-III), maximal numbers of PFC were attained 4 days after immunization; thereafter, the number of PFC decreased rapidly.
By contrast, serum antibody levels, which were measured in the same mice using a Farr test, reached peak values 5 days after immunization and then declined much more sowly than did the number of PFC.
Two factors were found to contribute to this disparity.
First, experiments conduceted with splenectomized mice showed that extrasplenic antibody synthesis, which began between days 3 and 4 after immunization and peaked on days 6 to 7, accounted for nearly one-third of the total amount of serum antibody produced.
Second, the average rate of antibody synthesis by PFC increased through day 6 after immunization and then declined.
Antigen-antibody dissociation tests showed that the avidity of the serum antibody obtained 4 to 7 days after immunization was the same.
Moreover, during the same interval, all the antibody detected by the Farr test was of the IgM class.
Thus, a change in avidity or class of immunoglobulin after day 5 did not account for the disparity observed.
The clearance rate of antibody injected i.
v.
into nonimmune and immunized mice was studied.
The data obtained indicated that accelerated clearance of antibody was occurring prior to day 3 after immunization; however, after day 3 the antibody clearance rate was constant and was the same as that found when antibody was injected into nonimmune mice.
These findings affirmed the results of previous studies showing that treadmill neutralization was not important in determining the serum antibody levels present after immunization with an optimally immunogenic dose of SSS-III.
Related Results
89Factors associated with pneumococcal nasopharyngeal carriage: a systematic review
89Factors associated with pneumococcal nasopharyngeal carriage: a systematic review
Abstract
Background
Pneumococcal disease is a major contributor to global childhood morbidity and mortality. Pneumococcal carria...
Factors associated with pneumococcal nasopharyngeal carriage: A systematic review
Factors associated with pneumococcal nasopharyngeal carriage: A systematic review
Pneumococcal disease is a major contributor to global childhood morbidity and mortality and is more common in low- and middle-income countries (LMICs) than in high-income countries...
Determinants of pneumococcal carriage by age in Africa (2000–2021): a systematic analysis
Determinants of pneumococcal carriage by age in Africa (2000–2021): a systematic analysis
Background
Streptococcus
pneumoniae
(
S. pneumoniae
...
Tamarind seed polysaccharide isolation from tamarind kernel powder by protease enzyme and high-intensity ultrasound
Tamarind seed polysaccharide isolation from tamarind kernel powder by protease enzyme and high-intensity ultrasound
Tamarind seed polysaccharide, xyloglucan (XG), is obtained from Tamarind Kernel Powder (TKP). In food industry, XG is widely used as a thickener, stabilizer, fat replacer, or starc...
Clinical streptococcal isolates, distinct from
Streptococcus pneumoniae,
but containing the β-glucosyltransferase
tts
gene and expressing serotype 37 capsular polysaccharide
Clinical streptococcal isolates, distinct from
Streptococcus pneumoniae,
but containing the β-glucosyltransferase
tts
gene and expressing serotype 37 capsular polysaccharide
The major virulence factor of the pneumococcus, and target for conjugate vaccines, is the polysaccharide capsule, which is usually encoded by the highly variable
...
Kinetics of the Antibody Response to Type III Pneumococcal Polysaccharide (SSS-III)
Kinetics of the Antibody Response to Type III Pneumococcal Polysaccharide (SSS-III)
Abstract
A simple method was described for the preparation of 125I-labeled type III pneumococcal polysaccharide (SSS-III*) with a high specific radioactivity which r...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Pneumococcal vaccination uptake and missed opportunities for vaccination among Canadian adults: A cross-sectional analysis of the Canadian Longitudinal Study on Aging (CLSA)
Pneumococcal vaccination uptake and missed opportunities for vaccination among Canadian adults: A cross-sectional analysis of the Canadian Longitudinal Study on Aging (CLSA)
Introduction
In Canada, pneumococcal vaccination is recommended to all adults aged ≥65 and those <65 who have one or more chronic medical conditions (CMCs). Understanding vaccin...

